Navigation

Costing tools

Costing tools are normally provided for each technology appraisal, quality standard, medical technology, diagnostic technology, clinical guideline and public health guidance. Costing tools are not provided for interventional procedures.

Types of costing tool

NICE provides five types of costing tool:

  • national cost reports summarise the national estimate cost and discuss the assumptions made when estimating the financial impact of implementing the guidance. For technology appraisals, the report is incorporated into the costing template.
  • costing templates support estimating the local cost of implementing guidance. and public health guidelines. These templates allow individual NHS organisations and local health economies to quickly assess the impact guidance will have on local budgets. A video tutorial explaining how to use the costing templates is available in Windows Media Player and Quick Time format.
  • business case. It presents the financial costs and benefits of implementing guidance.
  • cost impact and commissioning assessment for NICE quality standards
  • costing statements are used when cost impact is considered to be minimal to explain why the cost impact is not considered to be significant.
  • NICE support for commissioners and others using the quality standard

All guidance published since January 2005 has costing tools. Costing tools currently available are listed below.

Further information on the methodology for developing costing tools.

Results 61-80 of 515

Ref Title
TA246 Venom anaphylaxis - immunotherapy pharmalgen: costing statement
TA245 Venous thromboembolism - apixaban (hip and knee surgery): costing statement
TA244 Chronic obstructive pulmonary disease - roflumilast: costing statement
TA243 Follicular lymphoma - rituximab (review): costing statement
TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): costing statement
TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant): costing statement
TA239 Breast cancer (metastatic) - fulvestrant: costing statement
TA238 Arthritis (juvenile idiopathic, systemic) - tocilizumab: costing statement
TA236 Acute coronary syndromes - ticagrelor: costing template
TA235 Osteosarcoma - mifamurtide: costing template
TA233 Ankylosing spondylitis - golimumab: costing statement
TA232 Epilepsy (partial) - retigabine (adjuvant): costing statement
TA230 Myocardial infarction (persistent ST-segment elevation) - bivalirudin: costing template
TA229 Macular oedema (retinal vein occlusion) - dexamethasone: costing template
TA228 Multiple myeloma (first line) - bortezomib and thalidomide: costing template
TA227 Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): costing statement
TA226 Lymphoma (follicular non-Hodgkin's) - rituximab: costing template
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: costing statement
TA223 Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate: costing template
TA222 Ovarian cancer (relapsed) - trabectedin: costing statement

This page was last updated: 31 August 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.